Insulin detemir: from concept to clinical experience

Bibliography

• KRUSZYNSKA YT, HOME PD, HANNING I, ALBERTI KG: Basal and 24-h C-peptide and insulin secretion in normal man. Diabetologia (1987) 30:16-21.
   PubMed Web of Science ®Google Scholar
• POLONSKY KS, GIVEN BD, HIRSCH LJ et al.: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. (1988) 318(19):1231-1239.
   PubMed Web of Science ®Google Scholar
• HOME PD: Insulin therapy. In: International Textbook Of Diabetes Mellitus (2nd Edition). KG Alberti, RA De Fronzo, P Zimmet, H Keen (Eds), John Wiley, Chichester, UK (1997):899-928.
   Google Scholar
• HOME PD: Rapid-acting insulin secretagogues: a clinical need? Exp. Clin. Endocrinol. Diabetes (1999) 107(Suppl. 4):S115-S119.
   Google Scholar
• REICHARD O, NILSSON BY, ROSENQVIST U: The effect of long-term intensified insulin treatment in the development of micro-vascular complications of diabetes mellitus. N. Engl. J. Med. (1993) 329:304-309.
   PubMed Web of Science ®Google Scholar
• OHKUBO Y, KISHIKAWA H, ARAKI E et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. (1995) 28:103-117.
   PubMed Web of Science ®Google Scholar
• DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes (1996) 45:1289-1289.
   PubMed Web of Science ®Google Scholar
• DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes and the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329:977-986.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes mellitus. Lancet (1998) 352:837-853.
   PubMed Web of Science ®Google Scholar
• STRATTON IM, ADLER AI, NEIL HA et al.: Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. (2000) 321:405-412.
   PubMed Web of Science ®Google Scholar
• DECODE STUDY GROUP, EUROPEAN DIABETES EPIDEMIOLOGY GROUP: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet (1999) 354:617-621.
   PubMed Web of Science ®Google Scholar
• TOMINAGA M, IGARISHI K, EGUCHI H et al.: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care (1999) 22:920-924.
   PubMed Web of Science ®Google Scholar
• BRANGE J, RIBEL U, HANSEN JF et al.: Monomeric insulins obtained by protein engineering and their medical implications. Nature (1988) 333:679-682.
   PubMed Web of Science ®Google Scholar
• JØRGENSEN LN, DIDERIKSEN LH, DREJER K: Carcinogenic effect of human insulin analogue B10Asp in female rats. Diabetologia (1992) 35(1):A3.
   Google Scholar
• HANSEN BF, DANIELSEN GM, DREJER K et al.: Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem. J. (1996) 315(Pt 1):271-279.
   PubMed Web of Science ®Google Scholar
• KURTZHALS P, SCHAFFER L, SORENSEN A et al.: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49(6):999-1005.
   PubMed Web of Science ®Google Scholar
• BRANGE J, OWENS DR, KANG S, VOLUND AA: Monomeric insulins and their experimental and clinical implications. Diabetes Care (1990) 13:923-954.
   PubMed Web of Science ®Google Scholar
• LINDHOLM A: New insulins in the treatment of diabetes mellitus. Best Pract. Res. Clin. Gastroenterol. (2002) 16:475-492.
   PubMed Web of Science ®Google Scholar
• AHMED AB, HOME PD: Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diabetes Care (1998) 21:1707-1713.
   PubMedGoogle Scholar
• AHMED AB, MALLIAS J, HOME PD: Optimization of evening insulin dose in patients using the short-acting insulin analogue lispro. Diabetes Care (1998) 21:1162-1166.
   PubMedGoogle Scholar
• LALLI C, CIOFETTA M, DEL SINDACO P et al.: Long-term intensive treatment of Type 1 diabetes with the short- acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care (1999) 22:468-477.
   PubMed Web of Science ®Google Scholar
• SCOTT DA, FISHER AM: Studies on insulin with protamine. J. Pharmacol. Exp. Ther. (1936) 58:78-92.
   Google Scholar
• HAGEDORN HC, JENSEN BN, KRARUP NB, WODSTRUP I: Protamine insulinate. JAMA (1936) 106:177-180.
   Google Scholar
• KRAYENBÜHL C, ROSENBERG T: Crystalline protamine insulin. Rep. Steno. Mem. Hosp. (1946) 1:60-73.
   Google Scholar
• HEINEMANN L, LINKESCHOVA R, RAVE K, HOMPESCH B, SEDLAK M, HEISE T: Time action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care (2000) 23(5):644-649.
   PubMed Web of Science ®Google Scholar
• PLANK J, BODENLENZ M, SINNER F et al.: A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care (2005) 28(5):1107-1101.
   PubMed Web of Science ®Google Scholar
• THOW JC, HOME PD: Nocturnal hypoglycaemia. In: Hypoglycaemia and Diabetes. BM Frier, BM Fisher (Eds), Edward Arnold, London, UK (1993):199-211.
   Google Scholar
• MCCRIMMON RJ, FRIER BM: Hypoglycaemia, the most feared complication of insulin therapy. Diabetes Metab. (1994) 20:503-512.
   Web of Science ®Google Scholar
• STRAUSS GJ: Psychological factors in intensive management of insulin-dependent diabetes mellitus. Nurs. Clin. North Am. (1996) 31(4):737-745.
   PubMedGoogle Scholar
• GONDER-FREDERICK LA, COX DJ, KOVATCHEV B, JULIAN D, CLARKE WL: The psychosocial impact of severe hypoglycemic episodes on spouses of patients with IDDM. Diabetes Care (1997) 20(10):1543-1546.
   PubMed Web of Science ®Google Scholar
• GONDER-FREDERICK LA, CLARKE WL, COX DJ: The emotional, social, and behavioral implications of insulin-induced hypoglycemia. Semin. Clin. Neuropsychiatry (1997) 2(1):57-65.
   PubMedGoogle Scholar
• FRANCIS AJ, HOME PD, HANNING I, ALBERTI KG, TUNBRIDGE WM: Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br. Med. J. (1983) 286:1173-1176.
   PubMedGoogle Scholar
• LAURITZEN T, FABER OK, BINDER L: Variation in insulin absorption and blood glucose concentrations. Diabetologia (1979) 17:291-295.
   PubMed Web of Science ®Google Scholar
• GALLOWAY JA, SPRADLIN CT, NELSON RL, WENTWORTH SM, DAVIDSON JA, SWARNER JL: Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care (1981) 4(3):366-376.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L: Variability of insulin absorption and insulin action. Diabetes Technol. Ther. (2002) 4(5):673-682.
   PubMedGoogle Scholar
• HEISE T, NOSEK L, BIILMANN RØNN B et al.: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes. Diabetes (2004) 53:1614-1620.
   PubMed Web of Science ®Google Scholar
• TUNBRIDGE FK, NEWENS A, HOME PD et al.: Double-blind cross-over trial of isophane (NPH)- and lente-based insulin regimens. Diabetes Care (1989) 12:115-119.
   PubMedGoogle Scholar
• THOW JC, JOHNSTON AB, MARSDEN S, TAYLOR R, HOME PD: Morphology of palpably abnormal injection sites and effects on absorption of isophane (NPH) insulin. Diabetic Med (1990) 7:795-799.
   PubMedGoogle Scholar
• THOW JC, JOHNSTON AB, ANTSIFEROV M, HOME PD: Effect of raising injection site-skin temperature on isophane (NPH) insulin crystal dissociation. Diabetes Care (1989) 12:432-434.
   PubMed Web of Science ®Google Scholar
• JEHLE PM, MICHELER C, JEHLE DR, BREITIG D, BOEHM BO: Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet (1999) 354:1604-1607.
   PubMed Web of Science ®Google Scholar
• HOLMAN RR, STEEMSON J: OPID 174: a novel long-acting insulin preparation. Diabetic Med (1989) 6(Suppl. 1):A41.
   Google Scholar
• MARKUSSEN J, DIERS I, ENGESGAARD A et al.: Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. Protein Eng. (1987) 1(3):215-223.
   PubMedGoogle Scholar
• MARKUSSEN J, HOUGAARD P, RIBEL U, SORENSEN AR, SORENSEN E: Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng. (1987) 1(3):205-213.
   PubMedGoogle Scholar
• BOLLI GB, MARCHI RD, PARK GD et al.: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia (1999) 42:1151-1156.
   PubMed Web of Science ®Google Scholar
• BOLLI GB, OWENS DR: Insulin glargine. Lancet (2000) 356:443-445.
   PubMed Web of Science ®Google Scholar
• GARG SK, GOTTLIEB PA, HISATOMI ME et al.: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with Type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res. Clin. Pract. (2004) 66(1):49-56.
   PubMed Web of Science ®Google Scholar
• SCHOLTZ HE, VAN NIEKERK N, MEYER BH, ROSENKRANZ B: An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique [Abstract]. Diabetologia (1999) 42(Suppl. 1):A235.
   Google Scholar
• RATNER RE, HIRSCH IB, NEIFING JL, GARG SK, MECCA TE, WILSON CA, for the US Study Group of insulin glargine in Type 1 diabetes: less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. Diabetes Care (2000) 23:639-643.
   PubMed Web of Science ®Google Scholar
• PIEBER TR, EUGENE-JOLCHINE I, DEROBERT E: The European study group of HOE 901 in Type 1 diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes. Diabetes Care (2000) 23:157-162.
   PubMed Web of Science ®Google Scholar
• RASKIN P, KLAFF L, BERGENSTAL R, HALLE J-P, DONLEY D, MECCA T: A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH insulin used with insulin lispro in patients with Type 1 diabetes. Diabetes Care (2000) 23:1666-1667.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, PARK G, ZIMMERMAN J, FOR THE US INSULIN GLARGINE (HOE 901) TYPE 1 DIABETES INVESTIGATOR GROUP: Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. Diabetes Care (2000) 23:1137-1134.
   PubMed Web of Science ®Google Scholar
• SCHOBER E, SCHOENLE, VAN DYK J, WERNICKE-PANTEN K: The paediatric study group of insulin glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with Type 1 diabetes. Diabetes Care (2001) 24:2005-2006.
   PubMedGoogle Scholar
• YKI-JARVINEN H, DRESSLER A, ZIEMEN M; HOE 901/300S STUDY GROUP: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care (2000) 23(8):1130-1136.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, SCHWARTZ SL, CLARK CM Jr, PARK GD, DONLEY DW, EDWARDS MB: Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care (2001) 24(4):631-636.
   PubMed Web of Science ®Google Scholar
• RIDDLE MC, ROSENSTOCK J, GERICH J; INSULIN GLARGINE 4002 STUDY INVESTIGATORS: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care (2003) 26(11):3080-3086.
   PubMed Web of Science ®Google Scholar
• MASSI BENEDETTI M, HUMBURG E, DRESSLER A, ZIEMEN M: A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes. Horm. Metab. Res. (2003) 35(3):189-196.
   PubMed Web of Science ®Google Scholar
• FONSECA V, BELL DS, BERGER S, THOMSON S, MECCA TE: A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with Type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am. J. Med. Sci. (2004) 328(5):274-280.
   PubMed Web of Science ®Google Scholar
• KURTZHALS P, HAVELUND S, JONASSEN I et al.: Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. (1995) 312:725-731.
   PubMed Web of Science ®Google Scholar
• MARKUSSEN J, HAVELUND S, KURTZHALS P et al.: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia (1996) 39:281-288.
   PubMed Web of Science ®Google Scholar
• HAVELUND S, PLUM A, RIBEL U et al.: The mechanism of protraction of insulin detemir, a long-acting, acylated analogue of human insulin. Pharm. Res. (2004) 21(8):1498-1504.
   PubMed Web of Science ®Google Scholar
• WHITTINGHAM JL, HAVELUND S, JONASSEN I: Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry (1997) 36:2826-2823.
   PubMed Web of Science ®Google Scholar
• KURTZHALS P: Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int. J. Obes. (2004) 28(Suppl. 2):S23-S28.
   Web of Science ®Google Scholar
• HAMILTON-WESSLER M, ADER M, DEA M et al.: Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia (1999) 42:1254-1256.
   PubMed Web of Science ®Google Scholar
• HAMILTON-WESSLER M, ADER M, DEA MK et al.: Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb. Evidence for passive diffusion. Diabetes (2002) 51:574-582.
   PubMedGoogle Scholar
• DEA MK, HAMILTON-WESSLER M, ADER M et al.: Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes (2002) 51(3):762-769.
   PubMed Web of Science ®Google Scholar
• KURTZHALS P, HAVELUND S, JONASSEN I, MARKUSSEN J: Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J. Pharm. Sci. (1997) 86:1365-1368.
   PubMed Web of Science ®Google Scholar
• SORENSEN AR, TORNQVIST H: Effects of insulin detemir on glucose uptake and utilisation in human and rat adipocytes. Diabetes (2004) 53(Suppl. 2):A558.
   Google Scholar
• BODELIENZ M, SCHALLER MC, WUTTE A et al.: Measurement of insulin detemir and human insulin in adipose and muscle tissue of diabetic patients using open-flow microperfusion (Abstract). Diabetologia (2002) 45(Suppl. 2):A797.
   Google Scholar
• BRUNNER GA, SENDHOFER G, WUTTE A et al.: Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comnparison to NPH insulin in humans. Exp. Clin. Endocrinol. Diabetes (2000) 108(2):100-105.
   PubMed Web of Science ®Google Scholar
• HERMANSEN K, MADSBAD A, PERRILD H, KRISTENSEN A, AXELSEN M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care (2001) 24:296-301.
   PubMed Web of Science ®Google Scholar
• GRAY RS, SCHMITZ O, KRISTENSEN A, QWIST A, AXELSEN M: The dose response relationship between insulin detemir and NPH: A multi-centre, open, two-period, cross-over trial in insulin treated Type 2 diabetic patients (Abstract). Diabetes (2001) 50(Suppl. 2):A115.
   Google Scholar
• BOTT S, TUSEK C, JACOBSEN LV, KRISTENSEN A, HEISE T: Insulin detemir reaches steady-state after the first day of treatment and shows a peakless time-action profile with twice daily-applications. Diabetologia (2003) 46(Suppl. 2):A271.
   Google Scholar
• STRANGE P, MCGILL J, MAZZEO M: Reduced pharmacokinetic (PK) variability of a novel, long-acting insulin analog. Diabetes (1999) 48(Suppl. 1):A103.
   Google Scholar
• DANNE T, LUPKE K, WALTE K, VON SCHUETZ W, GALL M-A: Insulin detemir is characterised by a consistent pharmacokinetic profile across age groups in children, adolescents, and adults with Type 1 diabetes. Diabetes Care (2003) 26:2359-2356.
   PubMed Web of Science ®Google Scholar
• JHEE SS, LYNESS WH, ROJAS PB, LEIBOWITZ MT, ZAROTSKY V, JACOBSEN LV: Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy Caucasian and Japanese American subjects. J. Clin. Pharmacol. (2004) 44(3):258-264.
   PubMedGoogle Scholar
• RAVE K, NOSEK L, HEINEMANN L, JACOBSEN LV: Insulin detemir and NPH insulin: Comparison of pharmacokinetic and pharmacodynamic properties in Japanese and Caucasian volunteers. Diabetes (2003) 52(Suppl.1):A453.
   PubMedGoogle Scholar
• TROUPIN B, ELBROEND B, BERNHARD R et al.: Similar pharmacodynamic and pharmacokinetic dose-response relationship of insulin detemir and NPH insulin in African Americans, Hispanics or Latinos and Caucasians. Diabetes (2005) 54(Suppl. 1):A113.
   Google Scholar
• JACOBSEN L, POPESCU G, PLUM A: Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia (2002) 45(Suppl. 2):A259.
   Web of Science ®Google Scholar
• MARSHALL SM, HOME PD, TAYLOR R, ALBERTI KG: Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions. Diabetic Med. (1987) 4:521-525.
   PubMedGoogle Scholar
• VAGUE P, SELAM J-L, SKEIE S et al.: Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycaemia than NPH insulin in patients with Type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care (2003) 26:590-596.
   PubMed Web of Science ®Google Scholar
• DE LEEUW I, SELAM J-L, SKEIE S et al.: Insulin detemir-based used in basal-bolus therapy in people with Type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diab. Obes. Metab. (2005) 7:73-82.
   PubMed Web of Science ®Google Scholar
• ROBERTS A, BAYER T, MUNKSGAARD E, LANG H, STANDL E: Efficacy and safety of 6-month treatment with insulin detemir in Type 1 diabetic patients on a basal/bolus regimen. Diabetologia (2001) 44(Suppl. 1):A207.
   Google Scholar
• STANDL E, LANG H, ROBERTS A: The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of Type 1 diabetes. Diabetes Technol. Ther. (2004) 6(5):579-588.
   PubMedGoogle Scholar
• RUSSELL-JONES D, DRAEGER E, SIMPSON R, BOLINDER J, HYLLEBERG B: Effects of once-daily insulin detemir or NPH insulin on blood glucose control in people with Type 1 diabetes using a basal-bolus regimen. Clin. Ther. (2004) 26:724-736.
   PubMed Web of Science ®Google Scholar
• HOME P, BARTLEY P, RUSSELL-JONES D et al.; STUDY TO EVALUATE THE ADMINISTRATION OF DETEMIR INSULIN EFFICACY, SAFETY AND SUITABILITY (STEADINESS) STUDY GROUP: Insulin detemir offers improved glycemic control compared with NPH insulin in people with Type 1 diabetes: a randomized clinical trial. Diabetes Care (2004) 27(5):1081-1087.
   PubMed Web of Science ®Google Scholar
• PIEBER TR, DRAEGER E, KRISTENSEN A, GRILL V: Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir versus morning plus bedtime NPH insulin. Diabet. Med. (2005) 22(7):850-857.
   PubMed Web of Science ®Google Scholar
• KOLENDORF K, PAVLIC-RENAR I, SANTEUSANIO F, PHILOTHEOU A, GALL M-A, HELLER S: Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with Type 1 diabetes. Diabetologia (2004) 47(Suppl. 1):A329.
   Google Scholar
• ROBERTSON K, SCHÖNLE E, GUCEV Z et al.: Benefits of insulin detemir over NPH insulin in children and adolescents with Type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia. Diabetologia (2004) 47(Suppl. 1):A32.
   Google Scholar
• HERMANSEN K, FONTAINE P, KUKOLJA KK, PETERKOVA V, LETH G, GALL MA: Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia (2004) 47:622-629.
   PubMed Web of Science ®Google Scholar
• RAŠLOVÁ K, BOGOEV M, RAZ I, LETH G, GALL M-A, HANCU M: Insulin detemir and insulin aspart: a promising basal-bolus regimen for Type 2 diabetes. Diab. Res. Clin. Pract. (2004) 66(2):193-201.
   PubMed Web of Science ®Google Scholar
• HAAK T, TIENGO A, DRAEGER E, SUNTUM M, WALDHÄUSL W: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with Type 2 diabetes. Diab. Obes. Metab. (2005) 7:56-64.
   PubMed Web of Science ®Google Scholar
• GRAY RS, SCHMITZ O, KRISTENSEN A, QWIST A, AXELSEN M: The dose relationship between insulin detemir and NPH: a multicentre, open, two-period, cross-over trial in insulin treated Type 2 diabetic patients. Diabetes (2001) 50(2):A115.
   Google Scholar
• HERMANSEN K, DEREZINSKI T, KIM H, GALL MA: Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes. Diabetologia (2004) 47(Suppl. 1):A273.
   Google Scholar
• HELLER S, KIM H: Insulin detemir reduces hypoglycemic risk at comparable HbA1c values compared to NPH in patients with Type 1 diabetes. Diabetes (2005) 54(Suppl. 1):A120.
   Google Scholar
• ROBERTSON K, GALL M-A: Insulin detemir, but not NPH insulin, shifts body mass index towards population norms in insulin-treated young people with Type 1 diabetes. Diabet. Med. (2005) 22(Suppl. 2):P66.
   Google Scholar
• HOME PD: Intensive insulin therapy in clinical practice. Diabetologia (1997) 40(Suppl. 2):S83-S87.
   Google Scholar
• HERMANSEN K, TAMER S: The advantage of less weight gain increases with baseline obesity when insulin detemir rather than NPH Insulin is added to oral agents in Type 2 diabetes. Diabetes (2005) 54(Suppl. 1):A67.
   Google Scholar
• HELLER S, OLSEN KJ, DRAEGER E: Within-person variation in fasting blood glucose is correlated to incidence of hypoglycemia in people with Type 1 diabetes treated with insulin detemir and NPH. Diabetes (2004) 53(Suppl. 1):A426.
   PubMedGoogle Scholar
• ANDERSON JH, BRUNELLE RL, KOIVISTO et al.: Reduction of post-prandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Diabetes (1997) 46:265-270.
   PubMed Web of Science ®Google Scholar
• HOME PD, LINDHOLM A, RIIS A; EUROPEAN INSULIN ASPART STUDY GROUP: Insulin aspart versus human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet. Med. (2000) 17(11):762-770.
   PubMed Web of Science ®Google Scholar
• PICKUP J, MATTOCK M, KERRY S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with Type 1 diabetes: meta-analysis of randomised controlled trials. Br. Med. J. (2002) 324(7339):705.
   PubMed Web of Science ®Google Scholar
• PATEL BK, KOENIG JI, KAPLAN LM, HOOI SC: Increase in plasma leptin and Lep mRNA concentrations by food intake is dependent on insulin. Metabolism (1998) 47(5):603-607.
   PubMed Web of Science ®Google Scholar
• MCGOWAN MK, ANDREWS KM, KELLY J, GROSSMAN SP: Effects of chronic intrahypothalamic infusion of insulin on food intake and diurnal meal patterning in the rat. Behav. Neurosci. (1990) 104(2):373-385.
   PubMedGoogle Scholar
• OROSCO M, ROUCH C, GEROZISSIS K: Activation of hypothalamic insulin by serotonin is the primary event of the insulin-serotonin interaction involved in the control of feeding. Brain Res. (2000) 872(12):64-70.
   PubMed Web of Science ®Google Scholar
• SAUDEK CD: Novel forms of insulin delivery. Endocrinol. Metab. Clin. North Am. (1997) 26(3):599-610.
   PubMed Web of Science ®Google Scholar
• HORDERN SV, WRIGHT JE, UMPLEBY AM, SHOJAEE-MORADIE F, AMISS J, RUSSELL-JONES DL: Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia (2005) 48:420-426.
   PubMed Web of Science ®Google Scholar